Relating to the use of medication designated for treatment of respiratory distress on public and private school campuses.
Relating to the use of epinephrine auto-injectors and medication designated for treatment of respiratory distress on public and private school campuses.
Relating to the use of opioid antagonists on the campuses of public and private schools and institutions of higher education and at or in transit to or from off-campus school events.
Relating to the use of glucagon medication on certain public and private school campuses.
Relating to the use of prescription glucagon medication on public and private school campuses.
Relating to measures to prevent and respond to opioid-related drug overdoses, including policies and training regarding the use of opioid antagonists, at student residences on campuses of public institutions of higher education; providing immunity.
Relating to the administration of opioid antagonists by a school nurse at public school campuses.
Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.
Relating to training, preparedness, and funding for school safety and emergencies in public schools.
Relating to measures for ensuring safety and security in public schools, including measures related to the health and safety of public school students and active shooter training for certain peace officers.